REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) said the FDA placed a clinical hold on investigational gene therapies RGX-111 (MPS I) and RGX-121 (MPS II) after a single case of an intraventricular CNS tumor was found in a participant treated with RGX-111.
Preliminary analysis detected an AAV vector genome integration event linked to PLAG1 overexpression; causality is undetermined and the investigation is ongoing. The affected participant is asymptomatic with developmental gains. No neoplasm reported in nine other RGX-111 patients or 32 RGX-121 patients. REGENXBIO awaits the full FDA hold letter.
Positive
- Affected participant remains asymptomatic with developmental progress
- No neoplasm in nine other RGX-111 participants
- No neoplasm in 32 participants treated with RGX-121
Negative
- FDA placed clinical holds on RGX-111 and RGX-121 programs
- AAV vector integration detected with PLAG1 overexpression in tumor
- Ongoing investigation may delay development and access for MPS II
News Market Reaction – RGNX
On the day this news was published, RGNX declined 17.90%, reflecting a significant negative market reaction. Argus tracked a peak move of +10.2% during that session. Argus tracked a trough of -22.8% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $148M from the company's valuation, bringing the market cap to $679M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RGNX fell 3.21% while close peers showed mixed, mostly modest moves (e.g., ARCT +0.81%, KOD -3.8%). With no peers in the momentum scanner and no same-day peer news, the reaction appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Conference appearance | Neutral | +2.6% | Planned presentation at J.P. Morgan Healthcare Conference announced for Jan 2026. |
| Nov 25 | Investor conference | Neutral | +10.0% | Participation in Piper Sandler Healthcare Conference with scheduled fireside chat. |
| Nov 06 | Earnings and pipeline | Neutral | -3.8% | Q3 2025 financials and updated timelines for RGX-202 and RGX-121 programs. |
| Oct 30 | Pivotal enrollment | Positive | -0.2% | Completion of RGX-202 pivotal trial enrollment and initiation of commercial production. |
| Oct 29 | Earnings call setup | Neutral | -2.4% | Announcement of upcoming call to discuss Q3 2025 results and operations. |
Recent news and conference items have produced relatively modest single-day moves, with mixed reactions around earnings and operational updates.
Over the past few months, REGENXBIO has focused on clinical and corporate visibility, including conference appearances on Nov 25, 2025 and Dec 18, 2025, and pivotal RGX-202 enrollment completion on Oct 30, 2025. Q3 2025 results on Nov 6, 2025 highlighted $29.7M in revenue, a $61.9M net loss, and $302.0M in cash with runway into early 2027. Today’s regulatory hold on ultra-rare MPS programs contrasts with earlier progress-oriented updates.
Regulatory & Risk Context
The company filed an S-3 shelf registration on Nov 26, 2025, allowing it to offer and sell up to $300,000,000 of various securities over time. The filing indicates intended uses including clinical trial funding, capital expenditures, working capital, pipeline and commercial expansion, general expenses, potential debt repayment, and possible acquisitions or investments. Shelf usage count is 0, with no 424B prospectus supplements recorded so far.
Market Pulse Summary
The stock dropped -17.9% in the session following this news. A negative reaction despite the early, inconclusive nature of the safety signal fits the market’s tendency to de-risk on regulatory setbacks. The FDA’s clinical holds on RGX-111 and RGX-121 follow a single neoplasm case but affect two ultra-rare MPS programs that had shown encouraging profiles. Past news flow has focused on pipeline advancement, so sustained concern could hinge on further genetic analysis and updated FDA guidance.
Key Terms
clinical hold regulatory
investigational gene therapy medical
Phase I/II medical
neoplasm medical
CNS tumor medical
AAV vector medical
proto-oncogene medical
SAE medical
AI-generated analysis. Not financial advice.
The case was identified during a routine brain MRI of an asymptomatic five-year-old participant who received intracisternal RGX-111 four years prior. Preliminary genetic analysis of the resected tumor detected an AAV vector genome integration event associated with overexpression of a proto-oncogene (PLAG1), which is known to be susceptible to chromosomal rearrangements. The investigation to determine if this SAE is drug related is ongoing. The causality has not been established. The participant continues to be asymptomatic, with positive developmental advancements noted by the treating physician. No evidence of neoplasm has been reported in the nine other participants treated with RGX-111 nor in the 32 participants treated with RGX-121.
"We are surprised by FDA's decision to place our RGX-121 program on hold while the investigation of this single, inconclusive incident in RGX-111 continues," said Curran Simpson, President and CEO of REGENXBIO. "These are separate therapies, and the positive safety profile of RGX-121 in more than 30 patients treated, including those dosed nearly seven years ago, remains unchanged. Patient safety is our top priority, and we, our investigators, and the patient community remain confident in the benefit-risk ratio of RGX-121 and are highly encouraged by the meaningful efficacy profile demonstrated in the pivotal trial. RGX-121 presents an opportunity to address the urgent, significant unmet medical need in this ultra-rare disease community, and continued delay means continued neurodevelopmental decline in boys with MPS II."
REGENXBIO has not yet received the full clinical hold letter and awaits additional details from the FDA.
About RGX-121 (clemidsogene lanparvovec)
RGX-121 is a potential one-time gene therapy for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is structurally identical to normal I2S.
RGX-121 has received Orphan Drug Product, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA and advanced therapy medicinal products (ATMP) classification from the European Medicines Agency.
About Mucopolysaccharidosis Type II (MPS II)
MPS II, or Hunter Syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme I2S leading to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the central nervous system (CNS). In severe forms of the disease, early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. Specific treatment to address the neurological manifestations of MPS II remains a significant unmet medical need. Key biomarkers of I2S enzymatic activity in MPS II patients include its substrate CSF HS D2S6, which has been shown to correlate with neurocognitive manifestations of the disorder.
About RGX-111
RGX-111 is designed to use the AAV9 vector to deliver the α-l-iduronidase (IDUA) gene to the central nervous system (CNS). Delivery of the IDUA gene within the cells in the central nervous system (CNS) could provide a permanent source of secreted IDUA beyond the blood-brain barrier, allowing for long-term cross-correction of cells throughout the CNS. By providing rapid IDUA delivery to the brain, RGX-111 could potentially help prevent the progression of cognitive deficits that otherwise occurs in MPS I patients. RGX-111 has received orphan drug product, rare pediatric disease and Fast Track designations from the FDA.
About Mucopolysaccharidosis Type I (MPS I)
MPS I is a rare autosomal recessive genetic disease caused by a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA), leading to an accumulation of glycosaminoglycans (GAGs) including heparan sulfate (HS) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the central nervous system (CNS). This can include excessive accumulation of fluid in the brain, spinal cord compression, and cognitive impairment. MPS I is estimated to occur in 1 in 100,000 births. Current disease modifying therapies for MPS I include hematopoietic stem cell transplant (HSCT) and enzyme replacement therapy with a recombinant form of human IDUA administered intravenously. However, intravenous enzyme therapy does not treat the CNS manifestations of MPS I, and HSCT can be associated with clinically significant morbidity and mortality. Key biomarkers of IDUA enzymatic activity in MPS I patients include its substrate heparan sulfate (HS), which has been shown to correlate with neurocognitive manifestations of the disorder.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; NAVSUNLI for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2024, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Zolgensma® is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-regulatory-update-on-ultra-rare-mps-programs-302672061.html
SOURCE REGENXBIO Inc.
FAQ
Why did the FDA place a clinical hold on REGENXBIO's RGX-111 and RGX-121 (RGNX) on January 28, 2026?
How many patients treated with RGX-111 and RGX-121 were reported with neoplasm in the RGNX update?
What is known about the participant and tumor found in the RGX-111 study reported by RGNX?
Does REGENXBIO (RGNX) say the RGX-121 safety profile has changed after the FDA hold?
What immediate steps is REGENXBIO (RGNX) taking after the FDA clinical holds on January 28, 2026?
